{"id":"W2923666301","doi":"10.1038/s41408-019-0196-6","title":"Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Kite Pharma; National Institute for Health and Care Research; National Institutes of Health; American Society of Hematology; Cancer Research UK; National Cancer Institute; University College London; Celgene; University College London Hospitals NHS Foundation Trust; Sanofi; GlaxoSmithKline; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Internal medicine; Refractory (planetary science); Multiple myeloma; Interim analysis; Lenalidomide; Transplantation; Phases of clinical research; Clinical trial; Oncology; Gastroenterology; Surgery; Adverse effect; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005712041,0.0004351197,0.001671925,0.0006088347,0.0001741965,0.001406419,0.001094058,0.0007990086,0.001213326],"category_scores_gemma":[0.003312911,0.0002749206,0.000849626,0.0009037572,0.0004067312,0.0009466404,0.0003238138,0.00235,0.0005706914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006177241,"about_ca_system_score_gemma":0.0007660963,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006027064,"about_ca_topic_score_gemma":0.001593594,"domain_scores_codex":[0.9990872,0.0003216713,0.0001400417,0.00006950714,0.0003193245,0.00006229468],"domain_scores_gemma":[0.9973085,0.001329268,0.0004646669,0.0001219717,0.0006093043,0.0001663664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.005426941,0.0007356742,0.003947008,0.003805323,0.0005266856,0.0003830643,0.0002419305,0.001072524,0.02152656,0.0007830819,0.01502263,0.9465286],"study_design_scores_gemma":[0.0370296,0.08810278,0.09974389,0.004990363,0.005539485,0.007738673,0.0004362044,0.006423648,0.04971768,0.003589477,0.6964192,0.0002689649],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.287611,0.6613553,0.006581269,0.01173937,0.0009988426,0.0008118381,0.00196194,0.0006365825,0.02830395],"genre_scores_gemma":[0.4887178,0.4759474,0.009275444,0.01246081,0.00176679,0.0007308173,0.004695354,0.0003004665,0.006105174],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.005712041,"threshold_uncertainty_score":0.03020853,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02122107329605373,"score_gpt":0.3503603800385909,"score_spread":0.3291393067425372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}